Table 2 Treatment effectiveness at week 24 and 48 of treatment

HBV DNA undetectable, n(%)

5(19.23%)

24(54.55%)

8.399

0.004

HBV DNA < 2000, n(%)

8(30.77%)

37(84.09%)

20.239

0.000

HBeAg serological response, n(%)

7(26.92%)

9(20.45%)

0.388

0.533

HBeAg seroconversion, n(%)

6(23.08%)

9(20.45%)

0.067

0.796

ALT normalization, n(%)

7(26.92%)

29(65.91%)

9.944

0.002

HBsAg serological response, n(%)

1(3.85%)

0

1.717

0.371*

HBsAg seroconversion, n(%)

1(3.85%)

0

1.717

0.371*

Primary non-response

11(42.31%)

0

19.007

0.000*

Early virological response

5(20.83%)

24(54.55%)

8.399

0.004

HBV DNA undetectable, n(%)

14(53.85%)

30(68.18%)

1.439

0.230

HBV DNA < 2000, n(%)

17(65.38%)

38(86.36%)

4.272

0.039

HBeAg serological response, n(%)

12(46.15%)

15(34.09%)

1.004

0.316

HBeAg seroconversion, n(%)

10(38.46%)

15(34.09%)

0.136

0.798

ALT normalization, n(%)

12(46.15%)

38(86.36%)

12.948

0.000

HBsAg serological response, n(%)

6(23.08%)

2(4.54%)

3.865

0.045*

HBsAg seroconversion, n(%)

4(15.38%)

2(4.55%)

1.262

0.186*